Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Mexico / NCT07753993
Recruiting Phase 3

A Study to Investigate Outcomes With Elecoglipron Compared With Placebo in Adult Participants With Chronic Kidney Disease.

NCT07753993 · tracked via the Priya Life Science Mexico tracker
Sponsor
AstraZeneca
Phase
Phase 3
Started
2026-08-21
Last updated
2026-09-09

Condition(s) studied

Chronic Kidney Disease

Investigational drug(s) / intervention(s)

Elecoglipron →Placebo

Elecoglipron: Elicoglipron tablet

Placebo: Placebo tablet

Study summary

This is a Phase III, randomized, double-blind, parallel-group, placebo-controlled multicenter study to investigate outcomes with elecoglipron compared with placebo in participants with CKD with and without T2DM who are on background SGLT2i (dapagliflozin) as GDMT and other SoC treatments for CKD.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Adults with confirmed CKD; UACR ≥30 mg/g and eGFR ≥20 mL/min/1.73 m² within specified ranges. * On stable, patient maximum tolerated, labeled daily dose of ACEI or ARB for ≥4 weeks at least 28 days before screening. Exclusion Criteria: * BMI \<23 kg/m² at screening * History of type 1 diabetes mellitus * HbA1c ≥10% (86 mmol/mol) at screening * Currently receiving, or anticipated to receive, therapeutic intervention for diabetic retinopathy and/or macular edema. * Have had more than one episode of severe hypoglycemia within 180 days prior to screening, or hypoglycemia unawareness * Acute coronary syndrome, major cardiac procedure, stroke, or TIA within 3 months prior to screening * Clinically significant condition affecting the upper GI tract or chronic use of any medication that affects gastric motility or gastric emptying * History of acute or chronic pancreatitis * History/family history (first degree) of medullary thyroid cancer or MEN2

Primary outcome measure(s)

  • To evaluate the effect of elecoglipron compared with placebo in reducing the risk of the composite of ≥ 50% sustained decline in eGFR, ESKD, or all-cause mortality — Event-driven, trial is estimated to be up to 4.5 years
    Time to the first occurrence of any component of this composite: * ≥ 50% sustained decline in eGFR * ESKD defined as sustained eGFR \< 10 mL/min/1.73 m2, or Chronic dialysis treatment, or Receiving a renal transplant * All-cause mortality

Trial sites (715)

FacilityCityRegionStatus
Research Site Huntsville Alabama Not Yet Recruiting
Research Site Montgomery Alabama Not Yet Recruiting
Research Site Sheffield Alabama Not Yet Recruiting
Research Site Peoria Arizona Not Yet Recruiting
Research Site Phoenix Arizona Not Yet Recruiting
Research Site Surprise Arizona Not Yet Recruiting
Research Site Little Rock Arkansas Withdrawn
Research Site Chula Vista California Not Yet Recruiting
Research Site Concord California Not Yet Recruiting
Research Site Daly City California Not Yet Recruiting
Research Site Fremont California Not Yet Recruiting
Research Site Huntington Beach California Not Yet Recruiting
Research Site Huntington Park California Not Yet Recruiting
Research Site Lomita California Not Yet Recruiting
Research Site National City California Not Yet Recruiting
Research Site Northridge California Not Yet Recruiting
Research Site Northridge California Not Yet Recruiting
Research Site Rolling Hills Estates California Withdrawn
Research Site San Diego California Not Yet Recruiting
Research Site San Francisco California Withdrawn
Research Site San Mateo California Not Yet Recruiting
Research Site Tarzana California Not Yet Recruiting
Research Site Arvada Colorado Not Yet Recruiting
Research Site Denver Colorado Not Yet Recruiting
Research Site Hartford Connecticut Not Yet Recruiting
Research Site Middlebury Connecticut Not Yet Recruiting
Research Site Waterbury Connecticut Not Yet Recruiting
Research Site Boca Raton Florida Not Yet Recruiting
Research Site Boynton Beach Florida Not Yet Recruiting
Research Site Cutler Bay Florida Not Yet Recruiting
Research Site Fort Lauderdale Florida Not Yet Recruiting
Research Site Hollywood Florida Not Yet Recruiting
Research Site Jacksonville Beach Florida Not Yet Recruiting
Research Site Jensen Beach Florida Not Yet Recruiting
Research Site Lauderdale Lakes Florida Not Yet Recruiting
Research Site Longwood Florida Not Yet Recruiting
Research Site Melbourne Florida Not Yet Recruiting
Research Site Miami Florida Not Yet Recruiting
Research Site Miami Florida Not Yet Recruiting
Research Site Ocoee Florida Not Yet Recruiting

+ 675 more sites — see the full list on the official registry below.

More AstraZeneca trials in Mexico

Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Durvalumab Enrolling by invitation
A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC Active, not recruiting
An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) Active, not recruiting
Phase 3 Study of Anifrolumab in Adult Patients With Active Proliferative Lupus Nephritis Active, not recruiting
Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations Active, not recruiting

Other trials for the same condition

Type 2 Diabetes and Associated Factors in Mexico Enrolling by invitation
Dapagliflozin to Reduce the Decline in Renal Function in Patients Newly Diagnosed With Lupus Nephritis Active, not recruiting
A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes) Recruiting
A Study to Find Out How EMPAgliflozin is Tolerated and if it Helps Children and Adolescents With Chronic KIDNEY Disease (EMPA-KIDNEY® Kids) Recruiting
A Study Called FINE-REAL to Learn More About the Use of the Drug Finerenone in a Routine Medical Care Setting Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07753993 on ClinicalTrials.gov ↗ ← All trials in Mexico